Durvalumab and bevacizumab plus transarterial chemoembolization in unresectable hepatocellular carcinoma: a new paradigm?

Transl Gastroenterol Hepatol · 2026 · PMC12887335 · PMID 41675315

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In contrast, the arm that combined durvalumab with TACE (without bevacizumab) reported a median PFS of 10.0 months, which did not reach statistical significance vs.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.